January 7, 2026
France’s pharmacy network is under strain: in the past ten years, nearly 10% of pharmacies have closed (about 2,000 in total). In some rural communities, this trend is leading to a risk of a shortage of pharmacies.
To address this issue, an experimental solution has been developed: pharmacy branches
The very first pharmacy branch was officially authorized in 2022 in Tende (Alpes-Maritimes), under very unusual circumstances: the village had just been devastated by flooding caused by Storm Alex. The project, supported by the PACA Regional Health Agency (ARS) and the local Community Health and Social Services Committee (CPTS), aimed to restore access to healthcare for the town’s residents. However, due to an inability to recruit staff, the initiative struggled to gain momentum and ultimately never got off the ground.
Since the enactment of the Valletoux Act on December 27, 2023, local offices have benefited from a clear legal framework. The pilot program, led by the DGOS and the ARS, currently involves six pilot regions:
A total of six projects have been approved. Four branches are already operational, and additional openings are planned for the coming months.
The pilot program is governed by a set of specific guidelines. Among the main requirements are:
Hours of operation vary by project, ranging from a minimum of two half-days (8 hours) per week (La Chapelle d’Anguillon) to a minimum of four days (32 hours) per week (Coupiac).
Based on current projects, we can outline an initial typical profile:
The experiment is generating as much anticipation as it is skepticism.
In Cozzano (Corsica), the main pharmacy had to deal with unprecedented administrative and billing issues with the CPAM.
Other pharmacists, such as Angélique Siettel (Loire), highlight the logistical challenges: finding a location, the need to hire staff, adapting software, coordinating with wholesalers…
Among the unions, opinions are divided:
Is this a miracle solution to address the weakening of the regional network, or an open door to abuses that will further undermine it? This pilot program will provide the long-awaited answer. This is a development in the pharmaceutical landscape that warrants close attention, with the potential for significant impact in the coming years.